Trial Profile
An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary)
- Indications Giant lymph node hyperplasia
- Focus Adverse reactions
- Sponsors Janssen Research & Development; Janssen-Cilag
- 07 Jun 2022 Results of post-hoc analysis assessing safety and efficacy of on-label dosing, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 11 Feb 2020 Results published in the EUSA Pharma Media Release.
- 10 Feb 2020 Final results from this study have been published in The Lancet Haematology.